Stephen J. Polyak

Stephen J. Polyak

University of Washington

H-index: 54

North America-United States

About Stephen J. Polyak

Stephen J. Polyak, With an exceptional h-index of 54 and a recent h-index of 30 (since 2020), a distinguished researcher at University of Washington, specializes in the field of Virology, Cell Biology, Approved Drug Repurposing, Natural Products, inflammation.

His recent articles reflect a diverse array of research interests and contributions to the field:

Methods of modeling in vivo efficacy of drug combinations for treatment of viral infections

Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents

A unifying model to explain high nirmatrelvir therapeutic efficacy, low post-exposure prophylaxis efficacy, and frequent viral rebound

Virology under the microscope—a call for rational discourse

Antiviral efficacy of approved antiviral drugs and combinations thereof against CHIKV in human skin fibroblasts and AG129 mice

A unifying model to explain nirmatrelvir/ritonavir’s high efficacy during early treatment and low efficacy as post-exposure prophylaxis, and to predict viral rebound

Inhibition of arenaviruses by combinations of approved therapeutic drugs

Latent tuberculosis is associated with heightened levels of pro-and anti-inflammatory cytokines among Kenyan men and women living with HIV on long-term antiretroviral therapy

Stephen J. Polyak Information

University

Position

___

Citations(all)

11651

Citations(since 2020)

3455

Cited By

9616

hIndex(all)

54

hIndex(since 2020)

30

i10Index(all)

96

i10Index(since 2020)

62

Email

University Profile Page

University of Washington

Google Scholar

View Google Scholar Profile

Stephen J. Polyak Skills & Research Interests

Virology

Cell Biology

Approved Drug Repurposing

Natural Products

inflammation

Top articles of Stephen J. Polyak

Title

Journal

Author(s)

Publication Date

Methods of modeling in vivo efficacy of drug combinations for treatment of viral infections

2024/4/18

Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents

Antimicrobial Agents and Chemotherapy

Shuang Xu

Shadisadat Esmaeili

E Fabian Cardozo-Ojeda

Ashish Goyal

Judith M White

...

2024/4/3

A unifying model to explain high nirmatrelvir therapeutic efficacy, low post-exposure prophylaxis efficacy, and frequent viral rebound

medRxiv

Shadisadat Esmaeili

Katherine Owens

Jessica Wagoner

Stephen J Polyak

Judith M White

...

2024/1/30

Virology under the microscope—a call for rational discourse

Journal of virology

Felicia Goodrum

Anice C Lowen

Seema Lakdawala

James Alwine

Arturo Casadevall

...

2023/2/28

Antiviral efficacy of approved antiviral drugs and combinations thereof against CHIKV in human skin fibroblasts and AG129 mice

Sam Verwimp

Rana Abdelnabi

Johan Neyts

Stephen J Polyak

Leen Delang

2023/9/25

A unifying model to explain nirmatrelvir/ritonavir’s high efficacy during early treatment and low efficacy as post-exposure prophylaxis, and to predict viral rebound

S Esmaeili

K Owens

J Wagoner

SJ Polyak

JT Schiffer

2023/8/24

Inhibition of arenaviruses by combinations of approved therapeutic drugs

2023/7/6

Latent tuberculosis is associated with heightened levels of pro-and anti-inflammatory cytokines among Kenyan men and women living with HIV on long-term antiretroviral therapy

AIDS

Tecla M Temu

Stephen J Polyak

Celestine N Wanjalla

Nelson Aringo Mandela

Smritee Dabee

...

2023/6/1

Modulation of in Vitro SARS-CoV-2 Infection by Stephania tetrandra and Its Alkaloid Constituents

Journal of Natural Products

Aswad Khadilkar

Zoie L Bunch

Jessica Wagoner

Vandana Ravindran

Jessica M Oda

...

2023/4/12

Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network

Briefings in Bioinformatics

Vandana Ravindran

Jessica Wagoner

Paschalis Athanasiadis

Andreas B Den Hartigh

Julia M Sidorova

...

2022/11

Combinations of host-and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2

Microbiology spectrum

Jessica Wagoner

Shawn Herring

Tien-Ying Hsiang

Aleksandr Ianevski

Scott B Biering

...

2022/10/26

Mono-and combinational drug therapies for global viral pandemic preparedness

Aleksandr Ianevski

Rouan Yao

Ronja M Simonsen

Vegard Myhre

Erlend Ravlo

...

2022/4/15

Broad-spectrum mono-and combinational drug therapies for global viral pandemic preparedness

bioRxiv

Aleksandr Ianevski

Rouan Yao

Ronja M Simonsen

Vegard Myhre

Erlend Ravlo

...

2022/1/15

Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya

AIDS

Tecla M Temu

Jerry S Zifodya

Stephen J Polyak

Jessica Wagoner

Celestine N Wanjalla

...

2021/1/1

Inhibition of arenaviruses by combinations of orally available approved drugs

Antimicrobial agents and chemotherapy

Shawn Herring

Jessica M Oda

Jessica Wagoner

Delaney Kirchmeier

Aidan O’Connor

...

2021/3/18

Drug combinations as a first line of defense against coronaviruses and other emerging viruses

Judith M White

Joshua T Schiffer

Rachel A Bender Ignacio

Shuang Xu

Denis Kainov

...

2021/12/21

CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice

Molecular Therapy-Methods & Clinical Development

Daniel Stone

Kelly R Long

Michelle A Loprieno

Harshana S De Silva Feelixge

Elizabeth J Kenkel

...

2021/3/12

Evaluation of the potential of botanicals and their constituents against the SARS-CoV-2 virus

Planta Medica

Nadja B Cech

Aswad Khadilkar

Jessica Wagoner

Trevor Clark

Preston Manwill

...

2021/12

Human immunodeficiency virus is associated with higher levels of systemic inflammation among Kenyan adults despite viral suppression

Clinical Infectious Diseases

Sarah J Masyuko

Stephanie T Page

Stephen J Polyak

John Kinuthia

Alfred O Osoti

...

2021/10/1

Liver abnormalities after elimination of HCV infection: persistent epigenetic and immunological perturbations post-cure

Stephen J Polyak

I Nicholas Crispe

Thomas F Baumert

2021/1/7

See List of Professors in Stephen J. Polyak University(University of Washington)

Co-Authors

H-index: 114
Raymond Chung

Raymond Chung

Harvard University

H-index: 109
Michael Gale, Jr.

Michael Gale, Jr.

University of Washington

H-index: 69
Nicholas Oberlies

Nicholas Oberlies

University of North Carolina at Greensboro

H-index: 68
Volker Lohmann

Volker Lohmann

Ruprecht-Karls-Universität Heidelberg

H-index: 61
Stuart C. Ray, M.D.

Stuart C. Ray, M.D.

Johns Hopkins University

academic-engine